Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2021_LYSA_LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome
Blood . 2021 Jun 10;137(23):3251-3258.
En savoir plus
Lysa
2021_LYSA_Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified
Nat Commun . 2021 Jun 17;12(1):3705.
En savoir plus
Lysa
2021_LYSA_A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
Blood . 2021 May 13;137(19):2646-2656.
En savoir plus
Lysa
2021_LYSA_Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
Eur J Nucl Med Mol Imaging . 2021 May;48(5):1699-1700.
En savoir plus
Lysa
2021_LYSA_Mutational landscape of gray zone lymphoma.
Blood . 2021 Apr 1;137(13):1765-1776.
En savoir plus
Lysa
2021_LYSA_c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study
Front Oncol . 2021 Apr 20;11:638897.
En savoir plus
Lysa
2021_LYSA_Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
Blood Adv . 2021 Mar 23;5(6):1737-1745.
En savoir plus
Lysa
2021_LYSA_Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival
Blood Adv . 2021 Mar 23;5(6):1729-1732.
En savoir plus
Lysa
2021_LYSA_Improving high-resolution copy number variation analysis from next generation sequencing using unique molecular identifiers
BMC Bioinformatics . 2021 Mar 12;22(1):120. doi: 10.1186/s12859-021-04060-4.
En savoir plus
Lysa
2021_LYSA_Upfront eBEACOPP chemotherapy without consolidation radiotherapy in early-stage unfavourable Hodgkin lymphoma
Lancet Oncol . 2021 Feb;22(2):161-162. doi: 10.1016/S1470-2045(20)30640-9.
En savoir plus
Lysa
2021_LYSA_EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic
Hemasphere . 2021 Jan 27;5(2):e529. doi: 10.1097/HS9.0000000000000529.
En savoir plus
Lysa
2021_LYSA_The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial
Int J Cancer . 2021 Jan 1;148(1):150-160. doi: 10.1002/ijc.33202
En savoir plus
Lysa
2021_LYSA_Classical Hodgkin lymphoma
Lancet . 2021 Oct 23;398(10310):1518-1527. doi: 10.1016/S0140-6736(20)32207-8.
En savoir plus
Lysa
2021_LYSA_Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
J Nucl Med . 2021 Jan;62(1):30-36. doi: 10.2967/jnumed.120.242412
En savoir plus
Lysa
2020_LYSA_Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group
Hematol Oncol . 2020 Oct;38(4):446-455. doi: 10.1002/hon.2750.
En savoir plus
Lysa
2020_LYSA_Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T 3 phase IB trial of the LYSA
Ann Hematol . 2020 Aug;99(8):1771-1778. doi: 10.1007/s00277-020-04159-3.
En savoir plus
Lysa
2020_LYSA_Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
Blood Adv . 2020 Aug 11;4(14):3217-3223. doi: 10.1182/bloodadvances.2020001955.
En savoir plus
Lysa
2020_LYSA_Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network
Eur J Nucl Med Mol Imaging . 2020 Oct 24. doi: 10.1007/s00259-020-05080-7
En savoir plus
Lysa
2020_LYSA_Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
https://doi.org/10.1016/S2352-3026(20)30291-X
En savoir plus
Lysa
2020_LYSA_Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
https://doi.org/10.1016/S1470-2045(20)30441-1
En savoir plus
Lysa
2020_LYSA_Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
Blood. 2020 Nov 19;blood.2020008750. doi: 10.1182/blood.2020008750
En savoir plus
Lysa
2020_LYSA_Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Ann Oncol . 2020 Dec 2;S0923-7534(20)43174-6. doi: 10.1016/j.annonc.2020.11.019.
En savoir plus
Lysa
2020_LYSA_Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Blood Adv . 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001.
En savoir plus
Calym
2017_RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
2017. Jun 2;45(10):5639-5652.
En savoir plus